natgillin/translations-raw huggingface dataset:
The pyrazine derivatives in the light stabilising composition of the present invention typically contain a high fraction of di-substituted pyrazines. 
Derivati pirazina u pripravku za stabiliziranje na svjetlo iz ovog izuma tipično sadržavaju visok udio di-supstituiranih pirazina.
Method according to claim 15, wherein said flushing solution is expelled from a chamber inside said tube and said sample is introduced in said chamber. 
Postupak u skladu s patentnim zahtjevom 15, kod kojega se navedeno sredstvo za ispiranje istisne iz komore koja se nalazi unutar navedene cijevi i navedeni uzorak se uvede u navedenu komoru.
D comprises a radioisotope; and n is an integer from 1 to 20. 
D obuhvaća citotoksično sredstvo; i n je cijeli broj od 1 do 20.
Total weight mg Coating excipients, enough quantity to obtain a uniform coating comprising the following components: 
Ekcipijenti za presvlačenje, dovoljna količina da se dobije jednolična presvlaka koja|8 mg se satoji od slijedećih komponenti:
Microaggregation is thus a key feature of the PROLEUKIN™ product. 
Mikroagregacija je tako ključna značajka proizvoda PROLEUKINTM,
In some preferred embodiments, the polymer is hydroxypropyl methyl cellulose acetate succinate (HPMCAS). 
(HPMĆ) ili hidroksipropilmetilceluloza acetat sukcinat (HPMCAS).
In one embodiment, the animal does not express functional endogenous MHC I, II a, and/or II B polypeptides from the endogenous non-human MHC locus. 
Životinja prema zahtjevu 1, naznačena time, da životinja ne izražava funkcionalne endogene MHC-I-, II-a- i IIB-polipeptide iz endogenih ne-humanih MHC-loci na površinu stanice.
The first waterproofing layer 15 is provided by means of one or more sheets of EPDM (Ethylene-Propylene Diene Monomer), or other similar and equivalent materials having such elasticity properties as to allow the underlying ground to shift, as a consequence of geologic settlings or for other reasons, without causing problems to the waterproofing. 
Osnova sukladno jednom ili više prethodnih zahtjeva, naznačena time što je navedeni prvi vodootporni sloj (15) pružen posredstvom jednog ili više listova EPDM (etilen propilen dien monomer) ili drugog sličnog 1 ekvivalentnog materijala koji ima takve karakteristike elastičnosti da omogućuje tlu ispod pomicanje bez utjecaja na vodootpornost.
The rigid piston assembly according to claim 1, wherein the rigid piston further comprises a flow ring that gauges the amount of water to be flushed during operation. 
Sklop krutog klipa prema zahtjevu 1, naznačen time da kruti klip (310) dodatno sadrži protočni prsten koji mjeri količinu vode za ispiranje tijekom rada.
The method of claim 2, wherein the biological sample obtained from the subject is classified as negative for JCV antibody when the level of JCV antibody in the pre-incubated biological sample binding to the immobilized HPVLPs is approximately the same as the level of JCV antibody detected in the biological sample obtained from the subject that was pre-incubated in a solution without HPVLPs. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što biološki uzorak dobiven iz subjekta se klasificira kao negativan na protutijelo protiv ICV kada je razina protutijela protiv ICV u predinkubiranom biološkom uzorku koja se vežu na imobilizirane HPVLP-e otprilike ista kao razina protutijela protiv JCV detektirana u biološkom uzorku dobivenom iz subjekta predinkubiranom u otopini bez HPVLP-a.
of 3-pyridylborane derivative is used with respect to the triflate compound of formula (VI). 
derivata 3-piridilborana u odnosu na triflatni spoj formule (VI).
or a pharmaceutically acceptable salt thereof, wherein: 
HR P20100229 T1 ili njegova farmaceutski prihvatljiva sol, naznačen time da:
the cancer is selected from the group consisting of: glioblastoma, non-small cell lung cancer, lung cancer, colon cancer, head and neck cancer, breast cancer, squamous cell tumors, anal cancer, skin cancer, and vulvar cancer; or the cancer is selected from the group consisting of squamous tumors, glioblastoma, glioma, non-small cell lung cancer (NSCLC)squamous lung tumor, a squamous tumor of the head or neck, and a squamous cervical tumor: the cancer is a solid tumor having overexpression of EGFR. 
Formulacija za uporabu prema zahtjevu 20, naznačena time što je rak odabran iz skupine koja sadrži glioblastom, rak pluća ne-malih stanica, rak pluća, rak debelog crijeva, rak glave i vrata, rak dojke, tumore skvamoznih stanica, analni rak, rak kože, rak vulve, skvamozne tumore i gliom. Formulacija za uporabu prema zahtjevu 21, naznačena time što je skvamozni tumor odabran iz skupine koja se sastoji od skvamoznog tumora pluća, skvamoznog tumora glave ili vrata i skvamoznog tumora vrata maternice.
A, a main cross unit implementing a switching protocol to obtain and update a switching state and time slot configuration data, driving execution of system configuration, and sending the switching state and the time slot configuration data to secondary cross units; and 
A, glavnu jedinicu križanja koja provodi protokol prespajanja za postizanje i obnavljanje stanja prespajanja i podataka konfiguracije odsječka vremena, pogoni izvršavanje konfiguracije sustava 1 šalje stanje prespajanja 1 podatke konfiguracije odsječka vremena pomoćnim jedinicama križanja; i
The precipitate was then dried in a mortar by constant grinding using a pestle. 
Talog je zatim sušeni obrađen u tarioniku do konstantne veličine čestica pomoću lučka.
Yield: 60%; yellow oil. 
Prinos: 60%; žuto ulje.
The wet material was refluxed in 300 ml of methanol for 30 min and then filtered through a hyflow bed. 
Vlažni materijal je podvrgnut refluksu u 300 ml metanola tijekom 30 minuta i zatim filtriran kroz hyflow podlogu.
Drug combinations offering strong synergistic effects in vivo would therefor provide a major step forward. The present invention provides a novel combination comprising a B-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn-DDab-Dab-Trp-Dab-Dab-Ala-Ser-DPro-Pro) (I), wherein 
PATENTNI ZAHTJEVI Kombinacija koja sadrži peptidomimetik s (B-ukosnicom formule ciklo(-Thr-Trp-Ile-Dab-Orn-"Dab-Dab-Trp-Dab- Dab-Ala-Ser->Pro-Pro) (I), naznačena time što Dab je (S)-2,4-diaminobutanska kiselina;
The combustion chamber as claimed in claim 1, wherein a surface of said transition liner segment is coated with a thermal barrier coating (TBC), said surface being a hot gas side exposed to the axial flow of hot gases. 
Komora za izgaranje prema zahtjevu 1, naznačena time što je strana vrućeg plina navedenog segmenta obruča (22a) prekrivena s termičkom zaštitnom prevlakom (TBC) kako bi se omogućilo smanjenje masenog protoka rashladnog sredstva, što dovodi do učinkovitije sveukupne distribucije rashladnog zraka i zauzvrat do povoljnog emisijskog djelovanja plinske turbine (10).
In a special embodiment, the compounds of the invention are considered useful for the treatment, prevention or alleviation of anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias including social phobias, obsessive-compulsive disorder, and generalized or substance-induced anxiety disorder; 
Uporaba prema zahtjevu 4, naznačena time, što je bolest, poremećaj ili stanje depresija, kao što je panični poremećaj sa ili bez agorafobije, agorafobija bez povijesti paničnog poremećaja, strah od životinja i druge fobije, društvena fobija, opsesivno-kompulzivni poremećaj i opći ili posebni poremećaj uslijed depresije.
The device according to one of claims 1 to 4 wherein the transmitter, in operation, transmits assignment information indicating the allocated resource blocks to the terminal. 
Integrirani krug sukladno jednom od zahtjeva 1 do 5, naznačen time da su u prvoj dodjeli DVRB-ovi s uzastopnim DVRB brojevima dodijeljeni aparatu mobilnoj stanici.
The step (c) of separating the strands from each other comprises stirring the mixture of strands and watery solution of a flame retardant chemical composition, This may for example be done by mechanical stirring means know in the art. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time, da korak (c) međusobno odvajanje vlakana uključuje miješanje smjese vlakana i vodene otopine kemijskog sredstva za usporavanje plamena.
The method of claim 1, wherein no immunoaffinity chromatography is performed. 
Metoda 1z bilo kojeg od prethodnih patentnih zahtjeva, pri čemu se ne provodi imunoafinitetna kromatografija.
A computer program stored in a non-transient computer readable medium, the computer program comprising computer executable program code adapted to cause an apparatus to implement: 
Računalni program pohranjen na mediju koji računalo može očitati, računalni program obuhvaća programski kod koji računalo može provesti i koji je prilagođen da dovede do toga da uređaj implementira postupak prema bilo kojem od zahtjeva 1 do 6.
the compound of formula (XVI) is subjected to an alkylation reaction in the presence of a base and of a halogenated derivative Ra'X, Ra' being as defined in Claim 1 and X being a halogen. 
spoj s formulom (XVI) se podvrgava reakciji alkilacije u prisutnosti baze i halogeniranog derivata Ra'X, Ra' je kako je definirano u zahtjevu 1 i X je halogen.
At the end of the washing step, the solid component floats on the clean washing solution. 
Metoda u skladu sa patentnim zahtjevom 1, naznačena time da je pražnjenje čvrste komponente izvedeno pomoću:
X is a single bond, an oxygen atom, or a vinylene group; 
X predstavlja jednostruku vezu, atom kisika ili vinilensku skupinu;
Trivalent polypeptide that specifically binds protein F of hRSV, comprising or essentially consisting of at least one Nanobody chosen from the following: 
Trovalentni polipeptid koji je usmjeren protiv proteina F iz hRSV, koji se bira iz bilo kojeg od (A) do (C):
The polypeptide expression system of claim 28, wherein the PES2 encodes all or a portion of an antibody. 
Polipeptidni ekspresijski sustav prema patentnom zahtjevu 20, naznačen time, da PES2 kodira
The compound or salt of claim 1 selected from the group consisting of 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine:
iii) a dispersed phase comprising at least one solid or encapsulated pesticidally active ingredient or formulation aid. 
1i) disperznu fazu koja sadrži barem jednu krutu ili enkapsuliranu pesticidno aktivnu tvar ili pomoćno sredstvo za formulaciju.
A method according to claim 8, wherein the adjusted dose is the one, among the first and second doses, for which the absolute value of the variable B is lower. 
Metoda sukladno zaštiti 8, naznačena time što je prilagođena doza između prve i druge doze ta čija je apsolutna vrijednost varijable B niža.
Example 12: Specificity of the anti-IL-17 Nanobodies 
Datum objave europskog patenta:
The compound according to claim 8 having an XRPD as depicted in FIG. 2 . 
Spoj prema zahtjevu 17 koji ima XRPD kako je prikazan na Slici 2.
The apparatus of claim 1, wherein the entropy coder encodes positions of the non-zero coefficients and information for identifying the non-zero coefficients of each subset. 
Uređaj prema zahtjevu 1, naznačen time da entropijski koder (130) kodira položaje ne-nultih koeficijenata i informacije za identifikaciju ne-nultih koeficijenata svakog pod-bloka.
Package according to claim 26, characterised in that the lid (104, 105) is swivelably connected to the rear wall of the outer shell (102). 
Omot za pakiranje u skladu s patentnim zahtjevom 36, naznačen time što je poklopac (104, 105) spojen na stražnju stijenku vanjske ljuske (102) na takav način da se može zakretati.
The peptide according to any one of claims 1 to 3 for use in medicine. A host cell comprising the nucleic acid or the expression vector according to claim 4, wherein said host cell is not a human embryonic stem cell. 
Stanica domaćin koja se sastoji od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, pri čemu je stanica domaćin po mogućnosti stanica koja prezentira antigen, primjerice dendritična stanica, i pri čemu navedena stanica domaćin nije ljudska embrionska matična stanica.
The method of claim 4, wherein said crystalline salt is a 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosphoric acid salt. 
Postupak pripreme soli prema bilo kojem od patentnih zahtjeva od 1 do 5 koji podrazumijeva kombiniranje (R)-3-(4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropan-nitrila sa maleinskom kiselinom, sumpornom kiselinom ili fosfornom kiselinom.
post-operative (post-surgical), cancer or inflammatory pain 
postoperativna (post-kirurška) bol, rak ili upalna bol
an optional underlying primer coat; 
opcijskog donjeg temeljnog premaza;
A compound according to any one of claims 1 to 10 for use in the treatment or prevention of a condition or disorder selected from the group consisting of obesity, diabetes, anorexia nervosa, bulimia, cachexia, syndrome X, insulin resistance, hypoglycemia, hyperglycemia, hyperuricemia, hyperinsulinemia, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, nonalcoholic fatty liver disease, atherosclerosis, arteriosclerosis, acute heart failure, congestive heart failure, coronary artery disease, cardiomyopathy, myocardial infarction, angina pectoris, hypertension, hypotension, stroke, ischemia, ischemic reperfusion injury, aneurysm, restenosis, vascular stenosis, skin cancer, melanoma, lymphoma, breast cancer, lung cancer, colorectal cancer, stomach cancer, esophageal cancer, pancreatic cancer, prostate cancer, kidney cancer, liver cancer, bladder cancer, cervical cancer, uterine cancer, testicular cancer, ovarian cancer, and acne vulgaris. 
HR P20120029 T1 Spoj prema bilo kojem zahtjevu 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se koristi u liječenju pretilosti, dijabetesa, bulimije, sindroma X, inzulinske rezistencije, hipoglikemije, hiperglikemije, hiperurikemije, hiperinzulinemije, hiperkolesterolemije, hiperlipidemije, dislipidemije, miješane dislipidemije, hipertrigliceridemije, pankreatitisa i ne-alkoholne bolesti masne jetre, ateroskleroze, arterioskleroze, akutne srčane isuficijencije, kongestivne srčane isuficijencije, koronarno arterijske bolesti, kardiomiopatije, miokardijskog infarkta, angine pektoris, hipertenzije, hipotenzije, udara, ishemije, ishemijske reperfuzijske ozljede, aneurizma, restenoze i vaskularne stenoze.
Apply composite material 
Primjena kompozitnog materijala
The antibody or antibody fragment of claim 1, wherein said antibody or antibody fragment blocks binding of human PD-L1 and/or human PD-L2 to human PD-1 with an IC50 of about 1 nM or lower. 
2. Antitijelo ili fragment antitijela prema patentnom zahijevu 1, naznačen time što navedeno antitijelo ili fragment antitijela blokira vezanje humanog PD-L1 i/ili humanog PD-L2 za humani PD-1 sa ICs9 od oko 1 nM ili niže.
Dynamic light scattering 
Dinamičko svjetlosno raspršivanje
The present invention refers to a method for the detection of mutations at the EGFR gene in a blood sample from a subject said method comprising: 
Postupak detekcije mutacija u EGFR genu u uzorku krvi iz subjekta, naznačen time što se navedeni postupak sastoji u:
The pharmaceutical bag according to claim 7, wherein the cytotoxic drug is selected from the group consisting of: azacytidine, belinostat, bendamustine, brentuximab vedotin, bleomycin, bortezomib, busulfan, carboplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, decitabine, deferoxamine, doxorubicin, epirubicin hydrochloride, fludarabine, fotemustine, fulvestrant, gemcitabine, idarubicin, ifosfamide, irinotecan hydrochloride, ixabepilone, melphalan, methotrexate, oxaliplatin, paclitaxel, pemetrexed, pentostatin, raltitrexed, romidepsin, temozolomide, thiotepa, topotecan, trabectedin, trastuzumab, and vinblastine. 
Upotreba u skladu s bilo kojim prethodnim patentnim zahtjevom, naznačena time, da je citotoksični lijek odabran iz skupine koju čine: azacitidin, belinostat, bendamustin, brentuksimab vedotin, bleomicin, bortezomib, busulfan, karboplatin, ciklofosfamid, citarabin, dakarbazin, daktinomicin, daunorubicin, decitabin, deferoksamin, doksorubicin, epirubicin hidroklorid, fludarabin, fotemustin, fulvestrant, gemcitabin, idarubicin, ifosfamid, irinotekan hidroklorid, iksabepilon, melfalan, metotreksat, oksaliplatin, paklitaksel, pemetreksed, pentostatin, raltitreksed, romidepsin, temozolomid, tiotepa, topotekan, trabektedin, trastuzumab i vinblastin.
said boom of said crane unit comprises a transverse rail which extends in a direction which is essentially transverse to the longitudinal rail and essentially parallel to the centre line of the boom; 
- < navedeni krak navedene jedinice sa dizalicom obuhvaća dijagonalnu šinu (13) koja se pruža u smjeru koji je u osnovi dijagonalan u odnosu na uzdužnu šinu i u osnovi paralelan u odnosu na središnju liniju kraka;
The formulation in the form of suppository or vaginal ovule according to claim 15 wherein said composition consists of 5 to 17 parts by weight of beeswax, 5 to 25 parts by weight of honey, and 65 to 90 parts by weight of cocoa butter on a total of 100 parts by weight. 
Formulacija u obliku supozitorija ili vaginalete u skladu s patentnim zahtjevom 15, naznačena time, da se navedeni pripravak sastoji od 5 do 17 težinskih udjela pčelinjeg voska, 5 do 25 težinskih udjela meda i 65 do 90 težinskih udjela kakao maslaca od ukupno 100 težinskih udjela .
A method of controlling rust diseases on soybean plants, which comprises applying to the useful plants, the locus thereof or propagation material thereof a composition comprising a compound of formula (I) wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo. 
Pripravak pogodan za kontrolu bolesti uzrokovanih fitopatogenima koji se sastoji od: spoja formule (I) [image] naznačen time da R1 je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i
The compound, the polymorphic form, or the pharmaceutical composition for use according to claim 11, wherein the condition is a skin disease or disorder selected from dermatitis, a thermal or chemical burn, a chronic wound, acne, alopecia, other disorders of the hair follicle, epidermolysis bullosa, sunburn, complications of sunburn, a disorder of skin pigmentation, an aging-related skin condition, a post-surgical wound, a scar from a skin injury or burn, psoriasis, a dermatological manifestation of an autoimmune disease or a graft-versus host disease, skin cancer, and a disorder involving hyperproliferation of skin cells. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je kožna bolest ili poremećaj koji se bira od dermatitisa, toplinskih ili kemijskih opeklina, kronične rane, akni, alopecije, drugih poremećaja folikula kose, bulozne epidermolize, opeklina od sunca, komplikacija opeklina od sunca, poremećaja pigmentacije kože, stanja kože povezanog sa starenjem, rana nakon operacije, ožiljka od ozljede kože HR P20171275 T1 ili opeklina, psorijaze, dermatološke manifestacija autoimune bolesti ili bolesti presatka protiv domaćina, raka kože, te poremećaja koji obuhvaćaju hiperproliferaciju stanica kože.
separating the solvent layers; and 
(iii) odvajanja slojeva otapala; i
or a pharmaceutically acceptable salt, solvate, or hydrate thereof. 
C3.5 cikloalkil, ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat.
The partition wall element as claimed in claim 3, wherein a gaming machine, by means of its game sequence controller, may communicate with a display device and/or the lighting device via the interface in order to change contents and/or representations. 
Element pregradne stijenke sukladno bilo kojem od patentnih zahtjeva 4 do 5, naznačen time, što automat (28) za igru, pomoću svog upravljača za igranje igara, komunicira s uređajem (15) za prikaz i/ili rasvjetnim uređajem (36) putem sučelja (19, 29) kako bi se promijenili sadržaji i/ili prikazi.
Rather than use SDS in the processes and products of the invention, it is also possible to use sodium laureth sulfate (SLS) or ammonium lauryl sulfate (ALS). 
Više nego uporabu SDS u procesima i proizvodima iz izuma, također je moguće upotrijebiti natrijev lauret sulfat (SLS Sodium Laureth Sulfate) ili amonijev lauril sulfat (ALS - Ammonium Lauryl Sulfate).
a cartridge located within the housing and configured to hold a vaporizable substance; 
patronu (107) koja je oblikovana za držanje tvari za vaporizaciju;
The compound according to claim 11 for use in a method of treating heart failure (acute and chronic). 
Spoj prema zahtjevu 11, naznačen time, da se upotrebljava u postupku liječenja srčane insuficijencije (akutne 1 kronične).
A treated seed comprising a compound of claim 1 in an amount of from 0.0001 to 1% by weight of the seed before treatment. 
Tretirano sjeme koje sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 9 u količini od oko 0.0001 do 1 težinskih % sjemena prije tretmana.
The nucleic acid of claim 12, wherein the mutation is a substitution of alanine for arginine at position 37 of SEQ ID NO: 5. 
Pripravak za uporabu prema zahtjevu 18, naznačen time što se razmaknica sastoji od aminokiselina navedenih u SEQ ID NO: 51.
(b7) an antigen-binding site comprising an H chain CDR 1, 2, and 3 having at least 70% sequence identity with amino acid sequences of SEQ ID NOs: 126, 127, and 128, respectively; 
(b7) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 126, 127 odnosno 128 (H-lanac CDR-područja od J327);
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) klorotalonil.
Where appropriate, they can be prepared with coatings such as enteric coatings or they can be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art. 
Prema prikladnosti, mogu bili pripravljene s oblogom poput enterične ili se mogu formulirati tako da kontroliraju otpuštanje djelatne tvari u zadržanom ili produženom smislu na načine poznate struci.
As shown in the exemplary embodiment of FIG. 
Kako je prikazano na primjeru ostvarenja na Slici 1, posuda 101 je oblika metka.
The invention provides a solution in water comprising the following components at the following concentrations: 
Otopina u vodi, naznačena time što sadrži sljedeće komponente u sljedećim koncentracijama:
The following compounds were prepared in a similar way and analytical data are shown in Table 1: 
Slijedeći spojevi pripravljeni su na sličan način dok su analitički podaci prikazani u tabeli 1:
The placental stem cells for use of claim 1, wherein said method additionally comprises the use of an anti-macrophage inflammatory protein (MIP)-1a or anti-MIP-1B antibody, wherein said antibody is present in an amount sufficient to cause a detectable drop in the amount of MIP-1a or anti-MIP-1B in blood from a subject receiving said medicament. 
Matične stanice iz posteljice namijenjene upotrebi u skladu s patentnim zahtjevom 1, naznačene time što navedeni postupak dodatno uključuje upotrebu protumakrofagnog upalnog proteina (MIP)-1a ili protutijela protiv MIP-1B, gdje je navedeno protutijelo prisutno u količini dovoljnoj za uzrokovanje uočljivog smanjenja količine MIP-1a ili protutijela protiv MIP-1B u krvi iz subjekta koji prima navedeni medikament.
The Oxyntomodulin peptide analogue according to Claim 1, wherein the Cys residue at position 39 is absent, and the Cys residue at position 38 is PEGylated with an approximately 40 kDa PEG molecule and is optionally amidated. 
Peptidni analog oksintomodulina u skladu s patentnim zahtjevom 1, naznačen time što je Cys ostatak na položaju 39 odsutan, a Cys ostatak na položaju 38 je PEGiliran s približno 40 kDa molekula PEG i izborno je amidiran.